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MethOds: CiInl¢al, ang~ographio and procedural data were prospectively 
recorded, OCCL was verified by anglogrephy or autopsy, 
Results" The rate of OCCL was ~,3% and was associated with reajor 
cardiac events In 97%, Significant risk factors for OCCL, by Cox analy, 
sis were residual diesa¢:tlon iOR 10,2 [4,9-21,4]), overlapping stoats (OR 
1,g [1,04-3,60]) and postprocedurel therapy without ttclopldine (OR fi,2 
[2,4.,,11 ,B]), The rl.~k far OCCL, foil sharply after one week (loft graph), Title, 
pldtne was able to show Its full protootlvo effeot not before the third day after 
the procedure (fight graph), 
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Col¢luslons: The risk el OCCL depends mostly on the final result of sleet- 
Ing and poststontlng therapy, Ti~;Ioptdlno needs 2-3 days before dereostrating 
Its lull protective effeot, 
• Pmtmatment With Tl~lopldlne Reduces 
Non.Q-Wave Myooardlal  infarctions Fol lowing 
Intracomnary Slant ing 
S,R, Stoinhubt, M,S. L.eue~, D.P. Mukerjae, ~).J, Moliteme, S.G Ellis, 
E.J. Topoi, Cleveland Chn~c Founc/ation, Cleveland, OH, USA 
Background: Perl.procedural non~Q Mrs with PTCA are associated with en 
ir~craosed risk of late mortality, Aggressive antlptatolet therapy reduces the 
dsk of these events, We investigated whether pretreatm~nt with ticlopldina 
reduced the lectdence of non.Q wave Mrs followln 9 sleeting, 
Methods: The medical records of 175 patients WhO electively received o 
stoat end were pretmated with ticloptdine ware evaluated, 
Fiftdingts: 26% of these patients were treated with ticlopidine for 3 or 
mere days prior to the interventl0n, 46% for 1-2 d~,ys prior, and 2B% on the 
day el the procedure, ~llnlcal and procedural oharecteristics were similar in 
all 3 groups. Non,Q wave MI (CPK >210 IU/L) occurred significantly less 
frequently with increasing duration of therapy (Figure), 
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COnclusion: Tictopidine therapy pfiu, to s~enting decreases the incidence 
of non.O wave MI's ~n a dose-dependent manner, suggesting a critical rote 
for platelet inhibition in attenuating peri-procedural MI's. 
• TIGIopldln~.Asplrln as Antithrombotl¢ Regimen. 
for Intracorenary 6tenting for Unstable Angina: is 
there a Need for Further Antlplatetet Therapy? 
M, Angio~, N, Oonchln, C, Gsngloft, A, Grentzlngor, L. Jacquereln, V, Border, 
P, Houplun, Y, Jullli~re, F, Cherrier, Cardlologle, CHU Nancy, France 
Prior studios have shown significant Improvement of the results of balloon 
PT¢A In the setting of unstable angina using abcixireab. Nonafhelau in 
tllesa studies the usa of Intrecoronary Slanting was llreited, The aim of 
our study was to assess the In,h~pltal results of Intracoronsry =tenting 
with tiolopldlno,oSplrln therapy in unstable angina patients and to determine 
predlotom Of the Oocurrenco of reajor ¢~Implioatlons, 
We studied 17g oonsaoutlva patients (t44 men, moan ago 64 ~ 11 years) 
with PTGA from Novoreber 1094 to Oaceml~r tg96, without planned u~ 
of sbolxlmab, According to the Bmunwp.t~ classtfl~ation, 3?, pt~ (10%) w~m 
in 0tess I, g0 (85%) In class II and 40 (~7%) in clasP, Ill, in addition 15 pf~ 
(6%) had post myooardlal Inlarotlon unstable angina, indications for slanting 
ware', boil,out In 13 pie (7%), suboptimal results tn 1~4 pts (69%) and el~;tivO 
placement in 4~ pt~ (24%). In addition, 10 portents he~d unpl~nn~ use of 
eb¢iximob during the PTCA procedure, A reojer (;amp!italian (death, O,wav~ 
rnyocan~lial infarction, non Q,w~vo reyo~a~lial intamtion) accused tn 13 pfs 
(T,~%) alld (~llnl~l suca;0~a of th0 procedure (t~hnicpl s~oe~ of Ment 
placement without major complication) was a~hiaved in 09%, None of the 
p~tlents uncles/vent emergency GABG, Molar ~oreplcali~rl ote was 0% for 
cla~s i pts, 6,1% for aloes II Dis and t4,1% for class Ill pie (p < 0,04), On 
x,v~riate analysis, pmdiot~rs ot in,hoSpital major Coreplic~ttions were; LVEF 
(p ~-~ 0,04), steel indication (P ": O.Ot) an,:i unstable angina class (P ~ 0,06). 
Cc,nsiderlng postomy(~ardi~l nfar~tton a gina, meqor corepli~tion rate was 
5.1% in non class C pts end 2?% in class C pts (p ~ 0.01), this ditfi)ran¢;e 
remained slgnlllt;anl oven when b~ll.out procedures were excluded (p < 
0,01), 
Thus, the ree~or coreplication rate of coronap/stealing is high in class 111 
er C pts, despite the combined use of combined ticlopidine and aspinn. In 
such pts, the use of al~iximeb might be of padicular interest,. 
• Heparln DOSe Not Prevent Acute Slant 
....... :- Thrombos is  After Elective Intrecoronary Stent 
Implantat ion 
J, Suzuki, G. Hosokawa, H. Kaneda, S, Tanaka, S. Saito, 
St~onan,Karoakura General Hospital, Japan 
B~ckground: Several studies have reported that antiplatelet therapy ;ecrease 
stent throrebosts after elective sf~nt imptantatien. If coagulation activity dose 
not act as the main factor for acute stem thmmoosis, hepafin will have no 
influence on the thrombosis. 
Mefhocls: All patients were pre-traated with ticlopidine 200 mg and aspinn 
160 mg more than 2 days before the elective slant implantation. During the 
procedure we administered hepann 10,OOQ IU. After stentmg we ,~,ndomized 
to either a grasp inhibiting the hepann by protamine 100 mg or a satins 
group. We followed there for 3 days after and compared them for ACT, major 
bleeding, and cardiac events (acute steal thrombosis, death), 
Results: are summarized in the table below: 
protamtn e grotJp ._ sa!ino group P 
n 30 31 
ACT (second) 
5sin 14B ± 39 3re :L 7a ~0,001 
3hour 123 ± 20 202 • 50 40.001 
Complications 
Minor bleeding 0 4 0,O4 
Thrombosis 0 0 N~ 
Conclusion: The group using protamine did not increase acute stent 
thrombosis. Heparin dose not play the main factor for preventing acute st.. nt 
thrombosis after elective intracomnary srent implantation. 
